Estradiol Benzoate is a pro-drug ester of DB00783, a naturally occurring hormone that circulates endogenously within the human body. Estradiol is the most potent form of all mammalian estrogenic steroids and acts as the major female sex hormone. As a pro-drug of estradiol, estradiol benzoate therefore has the same downstream effects within the body through binding to the Estrogen Receptor (ER) including ER? and ER? subtypes, which are located in various tissues including in the breasts, uterus, ovaries, skin, prostate, bone, fat, and brain.
DB00783 is commonly produced with an ester side-chain as endogenous estradiol has very low oral bioavailability on its own (2-10%). First-pass metabolism by the gut and the liver quickly degrades the estradiol molecule before it gets a chance to enter systemic circulation and exert its estrogenic effects A12102. Esterification of estradiol aims to improves absorption and bioavailability after oral administration (such as with Estradiol valerate) or to sustain release from depot intramuscular injections (such as with Estradiol Cypionate) through improved lipophilicity. Following absorption, the esters are cleaved, resulting in the release of endogenous estradiol, or 17?-estradiol. Ester pro-drugs of estradiol are therefore considered to be bioidentical forms of estrogen T84.
Estradiol benzoate is not currently available in Canada or the US.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Tizanidine | The serum concentration of Tizanidine can be increased when it is combined with Estradiol benzoate. |
| Aripiprazole | The metabolism of Aripiprazole can be increased when combined with Estradiol benzoate. |
| Aripiprazole lauroxil | The metabolism of Aripiprazole lauroxil can be increased when combined with Estradiol benzoate. |
| Deferasirox | The serum concentration of Estradiol benzoate can be increased when it is combined with Deferasirox. |
| Peginterferon alfa-2b | The serum concentration of Estradiol benzoate can be increased when it is combined with Peginterferon alfa-2b. |
| Leflunomide | The serum concentration of Estradiol benzoate can be decreased when it is combined with Leflunomide. |
| Teriflunomide | The serum concentration of Estradiol benzoate can be decreased when it is combined with Teriflunomide. |
| Exenatide | Exenatide can cause a decrease in the absorption of Estradiol benzoate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Thalidomide | Estradiol benzoate may increase the thrombogenic activities of Thalidomide. |
| Zolmitriptan | The metabolism of Zolmitriptan can be decreased when combined with Estradiol benzoate. |
| Mifepristone | The serum concentration of Estradiol benzoate can be increased when it is combined with Mifepristone. |
| Ifosfamide | The metabolism of Ifosfamide can be increased when combined with Estradiol benzoate. |
| Perampanel | The metabolism of Perampanel can be increased when combined with Estradiol benzoate. |
| Warfarin | The metabolism of Warfarin can be increased when combined with Estradiol benzoate. |
| Acenocoumarol | The metabolism of Acenocoumarol can be increased when combined with Estradiol benzoate. |
| (R)-warfarin | The metabolism of (R)-warfarin can be increased when combined with Estradiol benzoate. |
| R,S-Warfarin alcohol | The metabolism of R,S-Warfarin alcohol can be increased when combined with Estradiol benzoate. |
| S,R-Warfarin alcohol | The metabolism of S,R-Warfarin alcohol can be increased when combined with Estradiol benzoate. |
| (S)-Warfarin | The metabolism of (S)-Warfarin can be increased when combined with Estradiol benzoate. |
| Zidovudine | The metabolism of Estradiol benzoate can be increased when combined with Zidovudine. |
| Ethinylestradiol | The metabolism of Estradiol benzoate can be increased when combined with Ethinylestradiol. |
| Testosterone propionate | The metabolism of Estradiol benzoate can be increased when combined with Testosterone propionate. |
| Prasterone | The risk or severity of adverse effects can be increased when Prasterone is combined with Estradiol benzoate. |
| Exemestane | The therapeutic efficacy of Exemestane can be decreased when used in combination with Estradiol benzoate. |
| Hyaluronidase (ovine) | The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Estradiol benzoate. |
| Hyaluronidase (human recombinant) | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Estradiol benzoate. |
| Hyaluronidase | The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Estradiol benzoate. |
| Lenalidomide | Estradiol benzoate may increase the thrombogenic activities of Lenalidomide. |
| Ospemifene | The risk or severity of adverse effects can be increased when Estradiol benzoate is combined with Ospemifene. |
| Abiraterone | The serum concentration of Estradiol benzoate can be increased when it is combined with Abiraterone. |
| Cetuximab | Estradiol benzoate may increase the thrombogenic activities of Cetuximab. |
| Human immunoglobulin G | Estradiol benzoate may increase the thrombogenic activities of Human immunoglobulin G. |
| Omalizumab | Estradiol benzoate may increase the thrombogenic activities of Omalizumab. |
| Gemtuzumab ozogamicin | Estradiol benzoate may increase the thrombogenic activities of Gemtuzumab ozogamicin. |
| Indium In-111 satumomab pendetide | Estradiol benzoate may increase the thrombogenic activities of Indium In-111 satumomab pendetide. |
| Trastuzumab | Estradiol benzoate may increase the thrombogenic activities of Trastuzumab. |
| Rituximab | Estradiol benzoate may increase the thrombogenic activities of Rituximab. |
| Basiliximab | Estradiol benzoate may increase the thrombogenic activities of Basiliximab. |
| Muromonab | Estradiol benzoate may increase the thrombogenic activities of Muromonab. |
| Digoxin Immune Fab (Ovine) | Estradiol benzoate may increase the thrombogenic activities of Digoxin Immune Fab (Ovine). |
| Ibritumomab tiuxetan | Estradiol benzoate may increase the thrombogenic activities of Ibritumomab tiuxetan. |
| Tositumomab | Estradiol benzoate may increase the thrombogenic activities of Tositumomab. |
| Alemtuzumab | Estradiol benzoate may increase the thrombogenic activities of Alemtuzumab. |
| Efalizumab | Estradiol benzoate may increase the thrombogenic activities of Efalizumab. |
| Antithymocyte immunoglobulin (rabbit) | Estradiol benzoate may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit). |
| Natalizumab | Estradiol benzoate may increase the thrombogenic activities of Natalizumab. |
| Palivizumab | Estradiol benzoate may increase the thrombogenic activities of Palivizumab. |
| Daclizumab | Estradiol benzoate may increase the thrombogenic activities of Daclizumab. |
| Bevacizumab | Estradiol benzoate may increase the thrombogenic activities of Bevacizumab. |
| Technetium Tc-99m arcitumomab | Estradiol benzoate may increase the thrombogenic activities of Technetium Tc-99m arcitumomab. |
| Eculizumab | Estradiol benzoate may increase the thrombogenic activities of Eculizumab. |
| Panitumumab | Estradiol benzoate may increase the thrombogenic activities of Panitumumab. |
| Ranibizumab | Estradiol benzoate may increase the thrombogenic activities of Ranibizumab. |
| Galiximab | Estradiol benzoate may increase the thrombogenic activities of Galiximab. |
| Pexelizumab | Estradiol benzoate may increase the thrombogenic activities of Pexelizumab. |
| Epratuzumab | Estradiol benzoate may increase the thrombogenic activities of Epratuzumab. |
| Bectumomab | Estradiol benzoate may increase the thrombogenic activities of Bectumomab. |
| Oregovomab | Estradiol benzoate may increase the thrombogenic activities of Oregovomab. |
| IGN311 | Estradiol benzoate may increase the thrombogenic activities of IGN311. |
| Adecatumumab | Estradiol benzoate may increase the thrombogenic activities of Adecatumumab. |
| Labetuzumab | Estradiol benzoate may increase the thrombogenic activities of Labetuzumab. |
| Matuzumab | Estradiol benzoate may increase the thrombogenic activities of Matuzumab. |
| Fontolizumab | Estradiol benzoate may increase the thrombogenic activities of Fontolizumab. |
| Bavituximab | Estradiol benzoate may increase the thrombogenic activities of Bavituximab. |
| CR002 | Estradiol benzoate may increase the thrombogenic activities of CR002. |
| Rozrolimupab | Estradiol benzoate may increase the thrombogenic activities of Rozrolimupab. |
| Girentuximab | Estradiol benzoate may increase the thrombogenic activities of Girentuximab. |
| Obiltoxaximab | Estradiol benzoate may increase the thrombogenic activities of Obiltoxaximab. |
| XTL-001 | Estradiol benzoate may increase the thrombogenic activities of XTL-001. |
| NAV 1800 | Estradiol benzoate may increase the thrombogenic activities of NAV 1800. |
| Briakinumab | Estradiol benzoate may increase the thrombogenic activities of Briakinumab. |
| Otelixizumab | Estradiol benzoate may increase the thrombogenic activities of Otelixizumab. |
| AMG 108 | Estradiol benzoate may increase the thrombogenic activities of AMG 108. |
| Iratumumab | Estradiol benzoate may increase the thrombogenic activities of Iratumumab. |
| Enokizumab | Estradiol benzoate may increase the thrombogenic activities of Enokizumab. |
| Ramucirumab | Estradiol benzoate may increase the thrombogenic activities of Ramucirumab. |
| Farletuzumab | Estradiol benzoate may increase the thrombogenic activities of Farletuzumab. |
| Veltuzumab | Estradiol benzoate may increase the thrombogenic activities of Veltuzumab. |
| Ustekinumab | Estradiol benzoate may increase the thrombogenic activities of Ustekinumab. |
| PRO-542 | Estradiol benzoate may increase the thrombogenic activities of PRO-542. |
| TNX-901 | Estradiol benzoate may increase the thrombogenic activities of TNX-901. |
| RI 624 | Estradiol benzoate may increase the thrombogenic activities of RI 624. |
| Stamulumab | Estradiol benzoate may increase the thrombogenic activities of MYO-029. |
| CT-011 | Estradiol benzoate may increase the thrombogenic activities of CT-011. |
| Leronlimab | Estradiol benzoate may increase the thrombogenic activities of Leronlimab. |
| Glembatumumab vedotin | Estradiol benzoate may increase the thrombogenic activities of Glembatumumab vedotin. |
| Olaratumab | Estradiol benzoate may increase the thrombogenic activities of Olaratumab. |
| IPH 2101 | Estradiol benzoate may increase the thrombogenic activities of IPH 2101. |
| TB-402 | Estradiol benzoate may increase the thrombogenic activities of TB-402. |
| Caplacizumab | Estradiol benzoate may increase the thrombogenic activities of Caplacizumab. |
| IMC-1C11 | Estradiol benzoate may increase the thrombogenic activities of IMC-1C11. |
| Eldelumab | Estradiol benzoate may increase the thrombogenic activities of Eldelumab. |
| Lumiliximab | Estradiol benzoate may increase the thrombogenic activities of Lumiliximab. |
| Ipilimumab | Estradiol benzoate may increase the thrombogenic activities of Ipilimumab. |
| Nimotuzumab | Estradiol benzoate may increase the thrombogenic activities of Nimotuzumab. |
| Clenoliximab | Estradiol benzoate may increase the thrombogenic activities of Clenoliximab. |
| BIIB015 | Estradiol benzoate may increase the thrombogenic activities of BIIB015. |
| Sonepcizumab | Estradiol benzoate may increase the thrombogenic activities of Sonepcizumab. |
| Motavizumab | Estradiol benzoate may increase the thrombogenic activities of Motavizumab. |
| Elotuzumab | Estradiol benzoate may increase the thrombogenic activities of Elotuzumab. |